|
1
|
Bandeira L and Bilezikian JP: Novel
therapies for postmenopausal osteoporosis. Endocrinol Metab Clin
North Am. 46:207–219. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kanis JA, Cooper C, Rizzoli R and
Reginster JY; Scientific Advisory Board of the European Society for
Clinical and Economic Aspects of Osteoporosis (ESCEO) and the
Committees of Scientific Advisors and National Societies of the
International Osteoporosis Foundation (IOF): European guidance for
the diagnosis and management of osteoporosis in postmenopausal
women. Osteoporos Int. 30:3–44. 2019. View Article : Google Scholar
|
|
3
|
Black DM and Rosen CJ: Clinical practice.
Postmenopausal osteoporosis. N Engl J Med. 374:254–262. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kespohl B, Schumertl T, Bertrand J, Lokau
J and Garbers C: The cytokine interleukin-11 crucially links bone
formation, remodeling and resorption. Cytokine Growth Factor Rev.
60:18–27. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Appelman-Dijkstra NM and Papapoulos SE:
Modulating bone resorption and bone formation in opposite
directions in the treatment of postmenopausal osteoporosis. Drugs.
75:1049–1058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li J, Li X, Liu D, Hamamura K, Wan Q, Na
S, Yokota H and Zhang P: eIF2α signaling regulates autophagy of
osteoblasts and the development of osteoclasts in OVX mice. Cell
Death Dis. 10:9212019. View Article : Google Scholar
|
|
7
|
Zhao F, Guo L, Wang X and Zhang Y:
Correlation of oxidative stress-related biomarkers with
postmenopausal osteoporosis: A systematic review and meta-analysis.
Arch Osteoporos. 16:42021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohamad NV, Ima-Nirwana S and Chin KY: Are
oxidative stress and inflammation mediators of bone loss due to
estrogen deficiency? A review of current evidence. Endocr Metab
Immune Disord Drug Targets. 20:1478–1487. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vatner SF, Zhang J, Oydanich M, Berkman T,
Naftalovich R and Vatner DE: Healthful aging mediated by inhibition
of oxidative stress. Ageing Res Rev. 64:1011942020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sies H and Jones DP: Reactive oxygen
species (ROS) as pleiotropic physiological signalling agents. Nat
Rev Mol Cell Biol. 21:363–383. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang FS, Wu RW, Chen YS, Ko JY, Jahr H and
Lian WS: Biophysical modulation of the mitochondrial metabolism and
redox in bone homeostasis and osteoporosis: How biophysics converts
into bioenergetics. Antioxidants (Basel). 10:13942021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khosla S and Hofbauer LC: Osteoporosis
treatment: Recent developments and ongoing challenges. Lancet
Diabetes Endocrinol. 5:898–907. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Arceo-Mendoza RM and Camacho PM:
Postmenopausal osteoporosis: Latest guidelines. Endocrinol Metab
Clin North Am. 50:167–178. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ensrud KE: Bisphosphonates for
postmenopausal osteoporosis. JAMA. 325:962021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Buckley L, Guyatt G, Fink HA, Cannon M,
Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, et
al: 2017 American college of rheumatology guideline for the
prevention and treatment of glucocorticoid-induced osteoporosis.
Arthritis Rheumatol. 69:1521–1537. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reid IR: A broader strategy for
osteoporosis interventions. Nat Rev Endocrinol. 16:333–339. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lv Z and Guo Y: Metformin and its benefits
for various diseases. Front Endocrinol (Lausanne). 11:1912020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Foretz M, Guigas B, Bertrand L, Pollak M
and Viollet B: Metformin: From mechanisms of action to therapies.
Cell Metab. 20:953–966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tseng CH: Metformin use is associated with
a lower risk of osteoporosis/vertebral fracture in Taiwanese
patients with type 2 diabetes mellitus. Eur J Endocrinol.
184:299–310. 2021. View Article : Google Scholar
|
|
20
|
Jiating L, Buyun J and Yinchang Z: Role of
metformin on osteoblast differentiation in type 2 diabetes. Biomed
Res Int. 2019:92039342019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, Sun Q, Jiang Q, Jiang Y, Zhang Y,
Cao J, Lu L, Li C, Wei P, Wang Q and Wang Y: Cryptotanshinone
ameliorates doxorubicin-induced cardiotoxicity by targeting
Akt-GSK-3β-mPTP pathway in vitro. Molecules. 26:14602021.
View Article : Google Scholar
|
|
22
|
Yang K, Cao F, Qiu S, Jiang W, Tao L and
Zhu Y: Metformin promotes differentiation and attenuates
H2O2-induced oxidative damage of osteoblasts via the
PI3K/AKT/Nrf2/HO-1 pathway. Front Pharmacol. 13:8298302022.
View Article : Google Scholar :
|
|
23
|
Yang K, Pei L, Zhou S, Tao L and Zhu Y:
Metformin attenuates H2O2-induced osteoblast
apoptosis by regulating SIRT3 via the PI3K/AKT pathway. Exp Ther
Med. 22:13162021. View Article : Google Scholar
|
|
24
|
Bai J, Xie N, Hou Y, Chen X, Hu Y, Zhang
Y, Meng X, Wang X and Tang C: The enhanced mitochondrial
dysfunction by cantleyoside confines inflammatory response and
promotes apoptosis of human HFLS-RA cell line via AMPK/Sirt 1/NF-κB
pathway activation. Biomed Pharmacother. 149:1128472022. View Article : Google Scholar
|
|
25
|
Zhang R, Li G, Zhang Q, Tang Q, Huang J,
Hu C, Liu Y, Wang Q, Liu W, Gao N and Zhou S: Hirsutine induces
mPTP-dependent apoptosis through ROCK1/PTEN/PI3K/GSK3β pathway in
human lung cancer cells. Cell Death Dis. 9:5982018. View Article : Google Scholar
|
|
26
|
Roskoski R Jr: Small molecule inhibitors
targeting the EGFR/ErbB family of protein-tyrosine kinases in human
cancers. Pharmacol Res. 139:395–411. 2019. View Article : Google Scholar
|
|
27
|
Wang S, Zhang Y, Wang Y, Ye P, Li J, Li H,
Ding Q and Xia J: Amphiregulin confers regulatory T cell
suppressive function and tumor invasion via the EGFR/GSK-3β/Foxp3
axis. J Biol Chem. 291:21085–21095. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sanchez-Rangel E and Inzucchi SE:
Metformin: Clinical use in type 2 diabetes. Diabetologia.
60:1586–1593. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cameron AR, Morrison VL, Levin D, Mohan M,
Forteath C, Beall C, McNeilly AD, Balfour DJ, Savinko T, Wong AK,
et al: Anti-inflammatory effects of metformin irrespective of
diabetes status. Circ Res. 119:652–665. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang TC, Duthie GG, Aucott LS and
Macdonald HM: Vitamin E homologues α- and γ-tocopherol are not
associated with bone turnover markers or bone mineral density in
peri-menopausal and post-menopausal women. Osteoporos Int.
27:2281–2290. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kulkarni AS, Gubbi S and Barzilai N:
Benefits of metformin in attenuating the hallmarks of aging. Cell
Metab. 32:15–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang T, Liu Q, Gao W, Sehgal SA and Wu H:
The multifaceted regulation of mitophagy by endogenous metabolites.
Autophagy. 18:1216–1239. 2022. View Article : Google Scholar :
|
|
33
|
Abate M, Festa A, Falco M, Lombardi A,
Luce A, Grimaldi A, Zappavigna S, Sperlongano P, Irace C, Caraglia
M and Misso G: Mitochondria as playmakers of apoptosis, autophagy
and senescence. Semin Cell Dev Biol. 98:139–153. 2020. View Article : Google Scholar
|
|
34
|
Panel M, Ghaleh B and Morin D:
Mitochondria and aging: A role for the mitochondrial transition
pore? Aging Cell. 17:e127932018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu Y, Yang M, Fan J, Peng Y, Deng L, Ding
Y, Yang R, Zhou J, Miao D and Fu Q: Deficiency of osteoblastic
Arl6ip5 impaired osteoblast differentiation and enhanced
osteoclastogenesis via disturbance of ER calcium homeostasis and
induction of ER stress-mediated apoptosis. Cell Death Dis.
5:e14642014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu P, Hu S, Jin Q, Li D, Tian F, Toan S,
Li Y, Zhou H and Chen Y: Ripk3 promotes ER stress-induced
necroptosis in cardiac IR injury: A mechanism involving calcium
overload/XO/ROS/mPTP pathway. Redox Biol. 16:157–168. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
NavaneethaKrishnan S, Rosales JL and Lee
KY: mPTP opening caused by Cdk5 loss is due to increased
mitochondrial Ca2+ uptake. Oncogene. 39:2797–2806. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nagini S, Sophia J and Mishra R: Glycogen
synthase kinases: Moonlighting proteins with theranostic potential
in cancer. Semin Cancer Biol. 56:25–36. 2019. View Article : Google Scholar
|
|
39
|
Lal H, Ahmad F, Woodgett J and Force T:
The GSK-3 family as therapeutic target for myocardial diseases.
Circ Res. 116:138–149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Morciano G, Naumova N, Koprowski P,
Valente S, Sardão VA, Potes Y, Rimessi A, Wieckowski MR and
Oliveira PJ: The mitochondrial permeability transition pore: An
evolving concept critical for cell life and death = The GSK-3
family as therapeutic target for myocardial diseases. Biol Rev Camb
Philos Soc. 96:2489–2521. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Karch J, Bround MJ, Khalil H, Sargent MA,
Latchman N, Terada N, Peixoto PM and Molkentin JD: Inhibition of
mitochondrial permeability transition by deletion of the ANT family
and CypD. Sci Adv. 5:eaaw45972019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang H, Ai J, Shopit A, Niu M, Ahmed N,
Tesfaldet T, Tang Z, Li X, Jamalat Y, Chu P, et al: Protection of
pancreatic β-cell by phosphocreatine through mitochondrial
improvement via the regulation of dual AKT/IRS-1/GSK-3β and
STAT3/Cyp-D signaling pathways. Cell Biol Toxicol. 38:531–551.
2022. View Article : Google Scholar
|
|
43
|
Hu Z, Crump SM, Zhang P and Abbott GW:
Kcne2 deletion attenuates acute post-ischaemia/reperfusion
myocardial infarction. Cardiovasc Res. 110:227–237. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ding L and Billadeau DD: Glycogen synthase
kinase-3β: A novel therapeutic target for pancreatic cancer. Expert
Opin Ther Targets. 24:417–426. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim DH, Triet HM and Ryu SH: Regulation of
EGFR activation and signaling by lipids on the plasma membrane.
Prog Lipid Res. 83:1011152021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu G, Xie Y, Su J, Qin H, Wu H, Li K, Yu
B and Zhang X: The role of EGFR signaling in age-related
osteoporosis in mouse cortical bone. FASEB J. 33:11137–11147. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Phukan S, Babu VS, Kannoji A, Hariharan R
and Balaji VN: GSK3beta: Role in therapeutic landscape and
development of modulators. Br J Pharmacol. 160:1–19. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang Z, Lv Z, Zhang W, Guo M and Li C: A
novel β-catenin from Apostichopus japonicus mediates Vibrio
splendidus-induced inflammatory-like response. Int J Biol Macromol.
156:730–739. 2020. View Article : Google Scholar : PubMed/NCBI
|
